+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Is there any association of osteoporosis with proton pump inhibitor use? (Gastroenterology 2010;138:896-904)



Is there any association of osteoporosis with proton pump inhibitor use? (Gastroenterology 2010;138:896-904)



Journal of Neurogastroenterology and Motility 16(3): 335-336




(PDF emailed within 0-6 h: $19.90)

Accession: 054003592

Download citation: RISBibTeXText

PMID: 20680177

DOI: 10.5056/jnm.2010.16.3.335


Related references

Canadian Association of Gastroenterology position statement: hip fracture and proton pump inhibitor therapy-a 2013 update. Canadian Journal of Gastroenterology 27(10): 593-595, 2014

Therapy of gastroesophageal reflux disease and functional dyspepsia overlaps with symptoms after usual-dose proton pump inhibitor: Acotiamide plus usual-dose proton pump inhibitor versus double-dose proton pump inhibitor. Journal of Gastroenterology and Hepatology 33(3): 623-630, 2017

Proton pump inhibitor therapy and osteoporosis. Current Drug Safety 3(3): 204-209, 2008

Proton pump inhibitor alone vs proton pump inhibitor plus mucosal protective agents for endoscopic submucosal dissection-induced ulcer: a systematic review and meta-analysis. Journal of Clinical Biochemistry and Nutrition 56(2): 85-90, 2015

Transcriptome analysis of proton pump inhibitor-responsive esophageal eosinophilia reveals proton pump inhibitor-reversible allergic inflammation. Journal of Allergy and Clinical Immunology 135(1): 187-197, 2015

Rebamipide plus proton pump inhibitor versus proton pump inhibitor alone in the treatment of endoscopic submucosal dissection-induced gastric ulcer: a meta-analysis of randomized controlled trials. Medicine 93(12): E64, 2014

Retraction. Rebamipide plus proton pump inhibitor versus proton pump inhibitor alone in treatment of endoscopic submucosal dissection-induced gastric ulcer: a meta-analysis of randomized controlled trials. Medicine 93(29): 399-399, 2015

Octreotide Added to a Proton Pump Inhibitor Versus a Proton Pump Inhibitor Alone in Nonvariceal Upper-Gastrointestinal Bleeds. Annals of PharmacoTherapy 2019: 1060028019833696, 2019

Validation of a short questionnaire in English and French for use in patients with persistent upper gastrointestinal symptoms despite proton pump inhibitor therapy: the PASS (Proton pump inhibitor Acid Suppression Symptom) test. Canadian Journal of Gastroenterology 19(6): 350-358, 2005

Proton pump inhibitor - side effects and complications of long-term proton pump inhibitor administration. Zeitschrift für Gastroenterologie 55(1): 63-74, 2017

Proton-pump inhibitor use is not associated with osteoporosis or accelerated bone mineral density loss. Gastroenterology 138(3): 896-904, 2010

The effects of risedronate administered in combination with a proton pump inhibitor for the treatment of osteoporosis. Journal of Bone and Mineral Metabolism 31(2): 206-211, 2013

Long-term proton pump inhibitor therapy and osteoporosis. Is there a real danger?. Orvosi Hetilap 154(26): 1005-1009, 2013

The therapeutic effectiveness of the coadministration of weekly risedronate and proton pump inhibitor in osteoporosis treatment. Journal of Osteoporosis 2014: 607145, 2014

Acid-related diseases. What is the current rescue treatment of choice for Helicobacter pylori: quadruple therapy (proton pump inhibitor, bismuth, tetracycline and metronidazole) or triple therapy with proton pump inhibitor, amoxicillin and levofloxacin?. Gastroenterologia Y Hepatologia 31(6): 400-401, 2008